This inventor holds 1 USPTO granted patent. Top assignee: Kukje Pharma Co., Ltd.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Younghoon Kim: Innovator in Pharmaceutical Chemistry
Introduction
Younghoon Kim is a notable inventor based in Gunpo, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that have therapeutic potential.
Latest Patents
Younghoon Kim holds a patent for an indole carboxamide derivative and a pharmaceutical composition containing the same. This patent describes indole carboxamide compounds of Formula (II) or pharmaceutically acceptable salts that inhibit the production of prostaglandin E (PGE) through the inhibition of microsomal prostaglandin E synthase-1 (mPGES-1). The compounds and their salts are effective in treating or preventing various conditions, including inflammation, arthritis, high fever, pain, cancer, stroke, and neurodegenerative diseases such as Alzheimer's disease. A pharmaceutical composition that includes the indole carboxamide compound as an active ingredient is also part of this patent.
Career Highlights
Younghoon Kim is associated with Kukje Pharma Co., Ltd., where he continues to advance his research and development efforts. His work has the potential to impact the pharmaceutical industry significantly, particularly in the treatment of inflammatory and neurodegenerative diseases.
Collaborations
Younghoon Kim collaborates with talented individuals in his field, including coworkers Jungmin Seo and Changmin Park. Their combined expertise contributes to the innovative research and development at Kukje Pharma Co., Ltd.
Conclusion
Younghoon Kim is a prominent inventor whose work in pharmaceutical chemistry is paving the way for new treatments for various medical conditions. His contributions are vital to advancing healthcare solutions and improving patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile